Recomgen Biotech

China
Guangzhou, Guangdong, China

Company profile

Recomgen Biotech company profile

Recomgen Biotech is an innovative biopharmaceutical company that focuses on large-scale serum-free continuous animal cell culture technology and the R&D of new biological drugs. Recomgen Biotech is working on developing rhTNK-tPA, a generation-specific thrombolytic drug that can be injected intravenously in a single dose, making it convenient for emergency treatment and out-of-hospital thrombolysis as needed. It improves the treatment rate, clinical benefit, and personal and societal medical burdens in patients with acute myocardial infarction who received thrombolytic therapy.

Business identity

Phone number
86-2082209991
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Founded
2000-10-01

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
4
Total equity funding
$9.2M
Last funding
Series C / $4.2M / 2019-10-14
Last equity funding
Series C / $4.2M
Investors
10
Lead investors
1
Exited on
2022-02-08

Founders and investors

Lead investors

Zhuhai Zhifan Qiye Guanli

Investors

CSC GroupFuho CapitalGuangzhou Financial Holding Fund ManagementNanhai Gangneng Fuel & MaterialsWanlian Tianze